István Gábor Takács is a human rights activist, videographer and trainer. He ran the Video Advocacy Program of the Hungarian Civil Liberties Union between 2007-2015. He worked as a needle exchange program counselor for 5 years. He is author of several articles on harm reduction and cameraman, editor, director and co-director of more than 700 online videos, among them longer documentaries, such as “Kostya Proletarsky” (2020), “Taking Back What’s Ours: An Oral History of the Movement of People who Use Drugs” (2020) ”A Day in the Life: The World of Humans Who Use Drugs” (2016), “Without Rights” (2009), “Without a Chance” (2014), “Room in the 8th District” (2014) and “The Invisible” (2011). Since 2016 he works at the Rights Reporter Foundation, where besides producing films, he is training activists in video advocacy.
Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender gap in psychedelic science, the importance of studying menstrual cycles, pregnancy, menopause, and women’s mental health, and how the field can become more inclusive and scientifically rigorous.
On 7 May 2026, policymakers, researchers, clinicians, people with lived experience, and civil society organisations gathered in Brussels for the inaugural meeting of the European Forum of National Psychedelic Societies. The meeting marked an important milestone in building a coordinated European movement to expand safe, evidence-based access to psychedelic-assisted therapies.
Watch Drugreporter’s short documentary, filmed at the seventh Interdisciplinary Conference on Psychedelic Research (ICPR) 2026 in Haarlem, the Netherlands, exploring how psychedelic science is evolving through conversations on Indigenous knowledge, therapy, consciousness, culture and the future of the field.
How can international human rights standards influence real-world drug policy reforms? From the abolition of the death penalty for drug offences in Pakistan to policy changes in Latin America and beyond, Drugreporter’s new short film explores how experts, activists, and policymakers have used the International Guidelines on Human Rights and Drug Policy to advocate for more humane and evidence-based approaches around the world.
In April 2026, drug user organizations, human rights advocates, researchers, and policymakers from across the Nordic region gathered in Oslo for the conference Nordic Mobilization on Human Rights and Drug Policy. The event marked the launch of a new Nordic network committed to promoting drug policies based on human rights, democracy, public health, and social justice.
At ICPR 2024, we talked to psychologist and psychotherapist Marc B. Aixalà about how so-called “bad trips” can be reframed as difficult but potentially transformative experiences, and the importance of integration in psychedelic therapy.
On 7 May 2026, PAREA convened the first European Forum of National Psychedelic Societies in Brussels, bringing together representatives from organisations in 25 countries working on psychedelic research, policy, and access across Europe. Watch key presentations on the state of psychedelic access in Europe, filmed by Drugreporter.
How could evidence-based psychedelic therapies help address war-related mental health challenges in Ukraine, particularly PTSD among veterans? This was the main question of the European Parliament event held on 6 May, which Drugreporter captured on video in its entirety. Watch the full session now!
As civic space shrinks and organized crime grows, the Nordic countries are at a crossroads. This conference brought together activists, researchers, policymakers, and people who use drugs to discuss solutions rooted in Nordic values. Watch all presentations filmed by Drugreporter here!
Tadeusz Hawrot is the founder of the Psychedelic Access and Research European Alliance (PAREA), a Brussels-based initiative working to prepare Europe for the integration of psychedelic-assisted therapies into healthcare systems. In this interview, he reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.
